Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release

Biomaterials

Volumn 75, Issue , 2016, Pages 193-202

  Luo, Dandan ^a   Carter, Kevin A ^a   Razi, Aida ^b   Geng, Jumin ^a   Shao, Shuai ^a   Giraldo, Daniel ^a   Sunar, Ulas ^c   Ortega, Joaquin ^b   Lovell, Jonathan F ^a  

^a University at Buffalo The State University of New York   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Wright State University   (United States)

Author keywords

Chemophototherapy; Chemotherapy; Doxorubicin; Liposomes; Phototherapy; Porphyrin phospholipid

Indexed keywords

CARDIOVASCULAR SYSTEM; CHEMOTHERAPY; INFRARED DEVICES; PHOSPHOLIPIDS; PORPHYRINS; TUMORS;

CHEMOPHOTOTHERAPY; DOXORUBICIN; INTRAVENOUS INJECTIONS; MAXIMUM TOLERATED DOSE; NEAR INFRARED LIGHT; PHOTOTHERAPY; STEALTH LIPOSOMES; TRIGGERED DRUG RELEASE;

LIPOSOMES;

DOXORUBICIN; LIPOSOME; PORPHYRIN PHOSPHOLIPID LIPOSOME; UNCLASSIFIED DRUG; CHOLESTEROL; MACROGOL DERIVATIVE; PHOSPHOLIPID; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; DISEASE ERADICATION; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RELEASE; DRUG STABILITY; DRUG TUMOR LEVEL; FEMALE; HEMODYNAMICS; INFRARED RADIATION; LIGHT TRIGGERED DRUG RELEASE; LIPOSOMAL DELIVERY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; HUMAN; METABOLISM; NEOPLASMS; NUDE MOUSE; TEMPERATURE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; CHOLESTEROL; DOXORUBICIN; DRUG LIBERATION; FEMALE; HUMANS; MICE, NUDE; NEOPLASMS; PHOSPHOLIPIDS; PHOTOTHERAPY; POLYETHYLENE GLYCOLS; PORPHYRINS; TEMPERATURE;

EID: 84946402931     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.027     Document Type: Article

References (63)

1. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 2001, 53:285-305.
2. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
3. Shum P., Kim J.-M., Thompson D.H. Phototriggering of liposomal drug delivery systems. Adv. Drug Deliv. Rev. 2001, 53:273-284.
4. Luo D., Carter K.A., Lovell J.F. Nanomedical engineering: shaping future nanomedicines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7:169-188.
5. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
6. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145.
7. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. 1991, 88:11460-11464.
8. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
9. Gabizon A.A., Barenholz Y., Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. 1993, 10:703-708.
10. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
11. Rivera E., Valero V., Esteva F.J., Syrewicz L., Cristofanilli M., Rahman Z., Booser D.J., Hortobagyi G.N. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother. Pharmacol. 2002, 49:299-302.
12. tm/doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449.
13. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000, 60:6950-6957.
14. Schroeder A., Honen R., Turjeman K., Gabizon A., Kost J., Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J. Control. Release 2009, 137:63-68.
15. Timko B.P., Dvir T., Kohane D.S. Remotely triggerable drug delivery systems. Adv. Mater. 2010, 22:4925-4943.
16. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 2008, 126:187-204.
17. Drummond D.C., Zignani M., Leroux J.-C. Current status of ph-sensitive liposomes in drug delivery. Prog. Lipid Res. 2000, 39:409-460.
18. Simões S., Moreira J.N., Fonseca C., Düzgüneş N., Pedroso de Lima M.C. On the formulation of ph-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 2004, 56:947-965.
19. Felber A.E., Dufresne M.-H., Leroux J.-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv. Drug Deliv. Rev. 2012, 64:979-992.
20. Leroux J.-C., Roux E., Le Garrec D., Hong K., Drummond D.C. N-Isopropylacrylamide copolymers for the preparation of ph-sensitive liposomes and polymeric micelles. J. Control. Release 2001, 72:71-84.
21. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. a new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60:1197-1201.
22. Lindner L.H., Eichhorn M.E., Eibl H., Teichert N., Schmitt-Sody M., Issels R.D., Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004, 10:2168-2178.
23. Basel M.T., Shrestha T.B., Troyer D.L., Bossmann S.H. Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS Nano 2011, 5:2162-2175.
24. de la Rica R., Aili D., Stevens M.M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 2012, 64:967-978.
25. Alvarez-Lorenzo C., Bromberg L., Concheiro A. Light-sensitive intelligent drug delivery systems†. Photochem. Photobiol. 2009, 85:848-860.
26. Carter K.A., Shao S., Hoopes M.I., Luo D., Ahsan B., Grigoryants V.M., Song W., Huang H., Zhang G., Pandey R.K., et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat. Commun. 2014, 5.
27. Podaru G., Ogden S., Baxter A., Shrestha T., Ren S., Thapa P., Dani R.K., Wang H., Basel M.T., Prakash P., et al. Pulsed magnetic field induced fast drug release from magneto liposomes via ultrasound generation. J. Phys. Chem. B 2014, 118:11715-11722.
28. Landon C.D., Park J.-Y., Needham D., Dewhirst M.W. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed. J. 2011, 3:38-64.
29. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12:991-1003.
30. Rai P., Mallidi S., Zheng X., Rahmanzadeh R., Mir Y., Elrington S., Khurshid A., Hasan T. Development and applications of photo-triggered theranostic agents. Adv. Drug Deliv. Rev. 2010, 62:1094-1124.
31. You J., Zhang G., Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano 2010, 4:1033-1041.
32. Ma Y., Liang X., Tong S., Bao G., Ren Q., Dai Z. Gold nanoshell nanomicelles for potential magnetic resonance imaging, light-triggered drug release, and photothermal therapy. Adv. Funct. Mater. 2013, 23:815-822.
33. Yang X., Liu X., Liu Z., Pu F., Ren J., Qu X. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv. Mater. 2012, 24:2890-2895.
34. Fomina N., Sankaranarayanan J., Almutairi A. Photochemical mechanisms of light-triggered release from nanocarriers. Adv. Drug Deliv. Rev. 2012, 64:1005-1020.
35. Carling C.-J., Viger M.L., Huu V.A.N., Garcia A.V., Almutairi A. In vivo visible light-triggered drug release from an implanted depot. Chem. Sci. R. Soc. Chem. 2015, 6:335-341. 2010.
36. Timko B.P., Arruebo M., Shankarappa S.A., McAlvin J.B., Okonkwo O.S., Mizrahi B., Stefanescu C.F., Gomez L., Zhu J., Zhu A., et al. Near-infrared-actuated devices for remotely controlled drug delivery. Proc. Natl. Acad. Sci. 2014, 111:1349-1354.
37. Dvir T., Banghart M.R., Timko B.P., Langer R., Kohane D.S. Photo-targeted nanoparticles. Nano Lett. 2010, 10:250-254.
38. Melancon M.P., Zhou M., Li C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc. Chem. Res. 2011, 44:947-956.
39. Timko B.P., Kohane D.S. Prospects for near-infrared technology in remotely triggered drug delivery. Expert Opin. Drug Deliv. 2014, 11:1681-1685.
40. Yatvin M., Weinstein J., Dennis W., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202:1290-1293.
41. Weinstein J.N., Magin R.L., Yatvin M.B., Zaharko D.S. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979, 204:188-191.
42. Ishida O., Maruyama K., Yanagie H., Eriguchi M., Iwatsuru M. Targeting chemotherapy to solid tumors with long-circulating thermosensitive liposomes and local hyperthermia. Jpn. J. Cancer Res. Gann 2000, 91:118-126.
43. Lovell J.F., Jin C.S., Huynh E., Jin H., Kim C., Rubinstein J.L., Chan W.C.W., Cao W., Wang L.V., Zheng G. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat. Mater. 2011, 10:324-332.
44. Rieffel J., Chen F., Kim J., Chen G., Shao W., Shao S., Chitgupi U., Hernandez R., Graves S.A., Nickles R.J., et al. Hexamodal imaging with porphyrin-phospholipid-coated upconversion nanoparticles. Adv. Mater. 2015, 27:1785-1790.
45. Zhang Y., Lovell J.F. Porphyrins as theranostic agents from prehistoric to modern times. Theranostics 2012, 2:905-915.
46. Huang H., Song W., Rieffel J., Lovell J.F. Emerging applications of porphyrins in photomedicine. Front. Phys. 2015, 3:23.
47. Shao S., Geng J., Ah Yi H., Gogia S., Neelamegham S., Jacobs A., Lovell J.F. Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens. Nat. Chem. 2015, 7:438-446.
48. He C., Liu D., Lin W. Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. ACS Nano 2015, 9:991-1003.
49. Ferrario A., Gomer C.J. Systemic toxicity in mice induced by localized porphyrin photodynamic therapy. Cancer Res. 1990, 50:539-543.
50. Veenhuizen R.B., Ruevekamp-Helmers M.C., Helmerhorst T.J.M., Kenemans P., Mooi W.J., Marijnissen J.P.A., Stewart F.A. Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and mTHPC. Int. J. Cancer 1994, 59:830-836.
51. Wooten R.S., Smith K.C., Ahlquist D.A., Muller S.A., Balm R.K. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg. Med. 1988, 8:294-300.
52. Carter K.A., Shao S., Hoopes M.I., Luo D., Ahsan B., Grigoryants V.M., Song W., Huang H., Zhang G., Pandey R.K., et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat. Commun. 2014, 5.
53. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta BBA - Biomembr. 1993, 1151:201-215.
54. Rohrbach D.J., Tracy E.C., Walker J., Baumann H., Sunar U. Blood flow dynamics during local photoreaction in a head and neck tumor model. Biomed. Phys. 2015, 3:13.
55. Lorusso D., Stefano A.D., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ("hand-foot" syndrome). Ann. Oncol. 2007, 18:1159-1164.
56. Lopez A.M., Wallace L., Dorr R.T., Koff M., Hersh E.M., Alberts D.S. Topical dmso treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother. Pharmacol. 1999, 44:303-306.
57. Gregoriadis G., Davis C. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochem. Biophys. Res. Commun. 1979, 89:1287-1293.
58. Kirby C., Clarke J., Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 1980, 186:591-598.
59. Li L.-B., Luo R.-C. Effect of drug-light interval on the mode of action of photofrin photodynamic therapy in a mouse tumor model. Lasers Med. Sci. 2009, 24:597-603.
60. Snyder J.W., Greco W.R., Bellnier D.A., Vaughan L., Henderson B.W. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 2003, 63:8126-8131.
61. Chen B., Pogue B.W., Luna J.M., Hardman R.L., Hoopes P.J., Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin. Cancer Res. 2006, 12:917-923.
62. Chen B., Pogue B.W., Goodwin I.A., O'Hara J.A., Wilmot C.M., Hutchins J.E., Jack Hoopes P., Hasan T. Blood flow dynamics after photodynamic therapy with verteporfin in the rif-1 tumor. Radiat. Res. 2003, 160:452-459.
63. Fingar V.H. Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg. 1996, 14:323-328.